Lisata Therapeutics (LSTA) and Kuva Labs, a subsidiary of Mi2 Holdings, said Tuesday they entered into a partnership and license agreement under which Kuva will leverage Lisata's iRGD cyclic peptide candidate, certepetide, as a targeting and delivery agent for its NanoMark platform.
Financial details weren't disclosed.
The partnership aims to create advanced magnetic resonance imaging agents for non-invasive detection of solid tumors, the company said, adding that Kuva will cover all development and commercialization costs, while Lisata will provide certepetide.
The agreement includes an upfront license fee, potential milestone payments, and royalties on future sales for Lisata, the companies added.
Price: 2.77, Change: +0.02, Percent Change: +0.65
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。